Incyte (INCY) vs NRC Health (NRC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
NRC Health (NRC) has outperformed Incyte (INCY) over the past year, gaining 71.3% versus a gain of 30.1%. Over five years, INCY leads with a +73.0% price change compared with -52.4% for NRC. Incyte is the larger company by market cap ($22.85 billion vs $451.7 million), about 50.6 times the size.
On valuation, Incyte trades at a lower forward P/E (12.9x vs 19.4x for NRC Health). NRC Health pays a dividend yielding 2.94%, while Incyte does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INCY | NRC |
|---|---|---|
| Share price | $112.75 | $20.42 |
| Market cap | $22.85B | $451.68M |
| 1-day change | -0.61% | +1.14% |
| YTD return | +14.85% | +8.79% |
| 1-year return | +30.14% | +71.31% |
| 5-year return | +73.03% | -52.38% |
| P/E ratio (TTM) | 14.36 | 85.08 |
| Forward P/E | 12.89 | 19.45 |
| EPS (TTM) | $7.85 | $0.24 |
| Dividend yield | 0.00% | 2.94% |
| Annual dividend | $0.00 | $0.60 |
| Revenue (latest FY) | $5.14B | — |
| Revenue growth (YoY) | +21.22% | — |
| Net income (latest FY) | $1.29B | — |
| Gross margin | 92.76% | — |
| Operating margin | 29.46% | — |
| Net margin | 25.03% | — |
| 52-week high | $132.60 | $23.68 |
| 52-week low | $82.82 | $11.01 |
| Distance from 52-week high | -14.97% | -13.77% |
| Analyst consensus | buy | none |
| Avg. price target upside | +14.53% | +27.33% |
| Average volume | 1.63M | 115.97K |
| Shares outstanding | 202.70M | 22.12M |
| Employees | 2,844 | 357 |
| Sector | Healthcare | Health Care |
| Industry | Biotechnology | Biotechnology: Commercial Physical & Biological Resarch |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Incyte is about 50.6 times larger than NRC Health by market value ($22.85B vs $451.68M).
- NRC has outperformed INCY by 41.2 percentage points over the past year.
- NRC Health trades at a higher earnings multiple (85.1x vs 14.4x trailing P/E).
- NRC Health offers a meaningfully higher dividend yield (2.94% vs 0.00%).
- The two companies sit in different sectors: Incyte in Healthcare and NRC Health in Health Care.
About Incyte
INCY stock →Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease.
Healthcare · Biotechnology · 2,844 employees
About NRC Health
NRC stock →NRC Health provides analytics and insights to measure and improve patient and employee experience for healthcare organizations in the United States. The company offers market experience solutions, a subscription-based services for improved tracking of awareness, perception, and consistency of healthcare brands; assessment of differentiators; and segmentation tools to evaluate the needs, wants, and behaviors of communities through assessments.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 357 employees
INCY vs NRC FAQ
Which is bigger, Incyte or NRC Health?
Incyte (INCY) is larger, with a market capitalization of $22.85B compared with $451.68M for NRC Health (NRC).
Which stock has performed better over the past year, INCY or NRC?
NRC returned +71.31% over the past 12 months, compared with +30.14% for INCY (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, INCY or NRC?
INCY has the lower trailing P/E at 14.4, versus 85.1 for NRC. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Incyte or NRC Health?
NRC Health pays a dividend yielding 2.94%, while Incyte does not currently pay a regular dividend.
Are Incyte and NRC Health in the same industry?
No. Incyte is in the Healthcare sector, while NRC Health is in Health Care.